Brief: Tiziana Life Sciences To Pursue Development Of Intranasal Foralumab For The Treatment Of Long COVID
13/04/2023 12:15
April 13 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES TO PURSUE DEVELOPMENT OF INTRANASAL
FORALUMAB FOR THE TREATMENT OF LONG COVID
* TIZIANA LIFE SCIENCES LTD - ANNOUNCED IT PLANS TO
INVESTIGATE
INTRANASAL FORALUMAB FOR TREATMENT OF LONG COVID
* TIZIANA LIFE SCIENCES LTD - PLAN TO FILE AN IND IN 4Q 2023
Source text for Eikon: ID:nGNXbpXGfH
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis